Note: *Co-first authors; §Co-corresponding authors. 

31. Jeong S*, Jang N*, Kim M, Choi IK. CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity. BMB Rep. 2023; 56(2):140-144.

30. Zhang B§, Choi IK§, Panaampon J, Wang Z. Does Delayed EBV Infection contribute to Rising Childhood Cancers? Trends Immunol. 2022; 43(12):956-958.

29. Zhang B, Choi IK. Facts and hopes in the relationship of EBV with cancer immunity and immunotherapy. Clin Cancer Res. 2022; 28(20):4363-4369.

28.  Choi IK*, Wang Z*, Ke Q, Hong M, Paul DW, Fernandes SM, Hu Z, Stevens J, Guleria I, Kim HJ, Cantor H, Wucherpfennig KW, Brown JR, Ritz J, Zhang B. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021; 590:157-162. 

27. Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, Liu Y, Kim HJ, Ritz J, Cantor H, Rajewsky K, Wucherpfennig KW, Zhang B. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses. Proc Natl Acad Sci U S A. 2018; 115(4):E686-E695.

26. Jung KH*, Choi IK*, Lee HS, Yan HH, Son MK, Ahn HM, Hong J, Yun CO, Hong SS. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Cancer Lett. 2017; 396:155-166. 

25. Oh E, Choi IK, Hong JW, Yun CO. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model. Oncotarget. 2017; 8(3):4730-4746.

24. Jeon YR, Ahn HM, Choi IK, Yun CO, Rah DK, Lew DH, Lee WJ. Hepatocyte growth factor-expressing adenovirus upregulates matrix metalloproteinase-1 expression in keloid fibroblasts. Int J Dermatol. 2016; 55(3):356-361.

23. Wares JR, Crivelli JJ, Yun CO, Choi IK, Gevertz JL, Kim PS. Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections. Math Biosci Eng. 2015; 12(6):1237-1256.

22. Choi IK*, Shin H*, Oh E, Yoo JY, Hwang JK, Shin K, Yu DC, Yun CO. Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus. Int J Cancer. 2015; 137(9):2253-2269. 

21. Kim PS, Crivelli JJ, Choi IK, Yun CO, Wares JR. Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. Math Biosci Eng. 2015; 12(4):841-858.

20. Lee WJ, Ahn HM, Roh H, Na Y, Choi IK, Lee JH, Kim YO, Lew DH, Yun CO. Decorin-expressing adenovirus decreases collagen synthesis and upregulates MMP expression in keloid fibroblasts and keloid spheroids. Exp Dermatol. 2015; 24(8):591-597.

19. Ryu J, Kaul Z, Yoon AR, Liu Y, Yaguchi T, Na Y, Ahn HM, Gao R, Choi IK, Yun CO, Kaul SC, Wadhwa R. Identification and functional characterization of nuclear mortalin in human carcinogenesis. J Biol Chem. 2014; 289(36):24832-24844.

18. Choi IK, Li Y, Oh E, Kim J, Yun CO. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-a-co-producing T cell-mediated antitumor immunity. PLoS One. 2013; 8(7):e67512.

17. Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol. 2013; 3:193.

16. Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther. 2013; 20(2):70-76.

15. Lee WJ*, Choi IK*, Lee JH, Kim YO, Yun CO. A novel 3-dimensional model system for keloid study: organotypic multicellular scar model. Wound Repair Regen. 2013; 21(1):155-165. 

14. Lim SA, Kim TJ, Lee JE, Sohn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KM. Ex vivo Expansion of Highly Cytotoxic Human NK Cells by Co-cultivation with Irradiated Tumor Cells for Adoptive Immunotherapy. Cancer Res. 2013; 73(8):2598-2607.

13. Koo T*, Choi IK*, Kim M, Lee JS, Oh E, Kim J, Yun CO. Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy. Hum Gene Ther. 2012; 23(6):609-622. 

12. Choi KJ*, Zhang SN*, Choi IK*, Kim JS, Yun CO. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther. 2012; 19(7):711-723. 

11. Lee WJ, Choi IK, Lee JH, Lee JS, Kim YO, Rah DK, Yun CO. Relaxin-expressing adenovirus decreases collagen synthesis and upragulate the MMP expression in Keloid fibroblasts: in vitro experiments. Plast Reconstr Surg. 2012; 130(3):407e-417e.

10. Koom WS, Park SY, Kim W, Kim M, Kim JS, Kim H, Choi IK, Yun CO, Seong J. Combination of Radiotherapy and Adenovirus-Mediated p53 Gene Therapy for MDM2-Overexpressing Hepatocellular Carcinoma. J Radiat Res. 2012; 53(2):202-210.

9. Choi IK, Lee JS, Zhang SN, Park J, Sonn CH, Lee KM, Yun CO. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther. 2011; 18(9):898-909.

8. Lee WJ, Yun CO, Yun IS, Kim YO, Choi IK, Yun TJ, Rah DK. Augmentation of rat skin flap viability by relaxin-expressing adenovirus. Wound Repair Regen. 2011; 19(6):709-717.

7. Lee WJ, Kim YO, Choi IK, Rah DK, Yun CO. Adenovirus-relaxin gene therapy for keloids: implication for reversing pathological fibrosis. Br J Dermatol. 2011; 165(3):673-677.

6. Yoon AR, Gao R, Kaul Z, Choi IK, Ryu J, Noble JR, Kato Y, Saito S, Hirano T, Ishii T, Reddel RR, Yun CO, Kaul SC, Wadhwa R. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. Nucleic Acids Res. 2011; 39(18):8078-8091.

5. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther. 2011; 19(8):1558-1568.

4. Choi IK*, Lee YS, Yoo JY*, Yoon AR, Kim H, Kim DS, Seidler DG, Kim JH, Yun CO. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther. 2010; 17(2):190-201. 

3. Wadhwa R, Ryu J, Gao R, Choi IK, Morrow G, Kaur K, Kim I, Kaul SC, Yun CO, Tanguay RM. Proproliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells. J Biol Chem. 2010; 285(6):3833-3839.

2. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee MG, Kim H, Yun CO. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther. 2010; 18(2):264-274.

1. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO. Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model. Clin Cancer Res. 2006; 12(19):5859-5868.